NASDAQ:RKDA - Arcadia Biosciences Stock Price, Price Target & More

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

Arcadia Biosciences Inc (NASDAQ:RKDA) posted its quarterly earnings results on Wednesday, May, 9th. The basic materials company reported ($4.86) EPS for the quarter. The basic materials company earned $0.21 million during the quarter. Arcadia Biosciences had a negative net margin of 686.10% and a negative return on equity of 259.46%. View Arcadia Biosciences' Earnings History.

Arcadia Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Arcadia Biosciences.

2 brokers have issued twelve-month price objectives for Arcadia Biosciences' stock. Their forecasts range from $20.00 to $20.00. On average, they expect Arcadia Biosciences' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 169.2% from the stock's current price. View Analyst Ratings for Arcadia Biosciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Arcadia Biosciences include Evogene (EVGN), China Green Agriculture (CGA), SenesTech (SNES), Kiwa Bio-Tech Products Group (KWBT), Eden Research (EDEN), Bion Environmental Technologies (BNET), Cavitation Technologies (CVAT) and Syngenta (SYT).

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

Headlines about RKDA stock have been trending positive on Saturday, Accern reports. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arcadia Biosciences earned a media sentiment score of 0.39 on Accern's scale. They also assigned media stories about the basic materials company an impact score of 49.35 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Arcadia Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (2.22%). Company insiders that own Arcadia Biosciences stock include Eric J Rey, Roger Salameh and Zhongjin Lu. View Institutional Ownership Trends for Arcadia Biosciences.

RKDA stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Arcadia Biosciences.

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of RKDA stock can currently be purchased for approximately $7.43.

Arcadia Biosciences has a market capitalization of $18.88 million and generates $4.03 million in revenue each year. The basic materials company earns $-15,700,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Arcadia Biosciences employs 42 workers across the globe.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]